Coronary side-effect potential of current and prospective antimigraine drugs.

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Circulation

• Publication date

  1998-07-07

• Fields of study

  Medicine

• Identifiers
  DOI 10.1161/01.CIR.98.1.25PMID 9665056
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmacokinetics of ergotamine in healthy volunteers following oral and rectal dosing

  2004cited by this paper
• Pharmacokinetics of methysergide and its metabolite methylergometrine in man

  2004cited by this paper
• Elucidation of the structure and receptor binding studies of the major primary, metabolite of dihydroergotamine in man

  2004cited by this paper
• Single dose pharmacokinetics of sumatriptan in healthy volunteers

  2004cited by this paper
• The comparison of the responsiveness of human isolated internal mammary and gastroepiploic arteries to levcromakalim: an alternative approach to the management of graft spasm.

  2003cited by this paper
• Initial human experience with MK-462 (rizatriptan): a novel 5-HT1D agonist.

  1997cited by this paper
• 311C90: Increasing the options for therapy with effective acute antimigraine 5HT1B/1D receptor agonists

  1997cited by this paper
• Receptor specificity and trigemino‐vascular inhibitory actions of a novel 5‐HT1B/1D receptor partial agonist, 311C90 (zolmitriptan)

  1997cited by this paper
• Naratriptan

  1997cited by this paper
• A study of the effects of sumatriptan on myocardial perfusion in healthy female migraineurs using 13NH3 positron emission tomography

  1997cited by this paper
• Chest Symptoms after Sumatriptan

  1996cited by this paper
• 5-HT1D receptor agonists and human coronary artery reactivity in vitro: crossover comparisons of 5-HT and sumatriptan with rizatriptan and L-741,519.

  1996cited by this paper
• Augmented contraction of the human isolated coronary artery by sumatriptan: a possible role for endogenous thromboxane

  1996cited by this paper
• Monthly Update: Central & Peripheral Nervous Systems: Pharmacology of antimigraine 5-HT1D receptor agonists

  1996cited by this paper
• Sumatriptan in clinical practice

  1996cited by this paper
• Congential Giant Aneurysms of the Left Atrial Appendage: Diagnosis and Management

  1996cited by this paper
• The tolerability and pharmacokinetics of the novel antimigraine compound 311C90 in healthy male volunteers.

  1996cited by this paper
• Rizatriptan vs sumatriptan in the acute treatment of migraine. A placebo-controlled, dose-ranging study. Dutch/US Rizatriptan Study Group.

  1996cited by this paper
• A comparison of the contractile effects of 5-hydroxytryptamine, sumatriptan and MK-462 on human coronary artery in vitro.

  1995cited by this paper
• Oral sumatriptan-associated transmural myocardial infarction

  1995cited by this paper
• Cardiac arrest following use of sumatriptan

  1995cited by this paper
• Endothelial nitric oxide and cardiovascular disease

  1994cited by this paper
• Is chest pain after sumatriptan oesophageal in origin?

  1994cited by this paper
• Variable Participation of 5‐HT1‐Like Receptors and 5‐HT2 Receptors in Serotonin‐Induced Contraction of Human Isolated Coronary Arteries: 5‐HT1‐Like Receptors Resemble Cloned 5‐HT1Dβ Receptors

  1994cited by this paper
• Variant angina complicating ergot therapy of migraine.

  1994cited by this paper
• Repeated endothelial removal augments intimal thickening and attenuates EDRF release.

  1994cited by this paper
• Sumatriptan Clinical Pharmacokinetics

  1994cited by this paper
• A multicentre, double-blind, placebo-controlled, dose-ranging study to investigate the efficacy and safety of oral doses dose of 311C90 in the acute treatment of migraine

  1994cited by this paper
• Intoxications of the nervous system

  1994cited by this paper
• Sumatriptan. A reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache.

  1994cited by this paper
• Interaction Between Thromboxane A2 and 5‐Hydroxytryptamine Receptor Subtpes in Human Coronary Arteries

  1993cited by this paper
• Sumatriptan and ischaemic heart disease.

  1993cited by this paper
• Sumatriptan and ischaemic heart disease

  1993cited by this paper
• Tumour HER2 protein in breast cancer and family history.

  1993cited by this paper
• Transmural myocardial infarction with sumatriptan.

  1993cited by this paper
• Sumatriptan and ischaemic heart disease.

  1993cited by this paper
• Effect of Subcutaneous Sumatriptan, a Selective 5HT1 Agonist, on the Systemic, Pulmonary, and Coronary Circulation

  1993cited by this paper
• Effect of Ketanserin on Proximal and Distal Coronary Constrictor Responses to Intracoronary Infusion of Serotonin in Patients With Stable Angina, Patients With Variant Angina, and Control Patients

  1992cited by this paper
• The safety and tolerability of sumatriptan: an overview.

  1991cited by this paper
• Myocardial Ischemia Related to Ergot Alkaloids: A Case Report and Literature Review

  1991cited by this paper
• Divergent effects of serotonin on coronary-artery dimensions and blood flow in patients with coronary atherosclerosis and control patients.

  1991cited by this paper
• 5-Hydroxytryptamine receptor profile in healthy and diseased human epicardial coronary arteries.

  1990cited by this paper
• 5-Hydroxytryptamine contracts human coronary arteries predominantly via 5-HT2 receptor activation.

  1989cited by this paper
• Intramuscular ergotamine: Plasma levels and dynamic activity

  1985cited by this paper
• Clinical Pharmacokinetics of Ergotamine in Migraine and Cluster Headache

  1985cited by this paper
• Bioavailability of dihydroergotamine in man.

  1982cited by this paper
• Effects of 5-Hydroxytryptamine and Ergotamine on Human Superficial Temporal Artery

  1981cited by this paper
• Acute Myocardial Infarction Induced by Ergotamine Tartrate: Possible Role of Coronary Arterial Spasm

  1981cited by this paper

• Structural basis of LY334370 recognition and selectivity at the 5-HT1F receptor.

  2026cites this paper
• Variant angina associated with a CGRP receptor antagonist: a case report

  2025cites this paper
• Functional crosstalk between the vanilloid and endocannabinoid systems in modulating vascular tone: implications for (neuro)vascular disorder therapy

  2025cites this paper
• Sensitizing effect of antimigraine drug sumatriptan on capsaicin-sensitive lung vagal neurons via 5-HT1B/1D receptors and PKA: Relevance to adverse chest effects

  2025cites this paper
• Sex differences in the vasoactive effect of transient receptor potential channels: TRPM3 as a new therapeutic target for (neuro)vascular disorders

  2025cites this paper
• Treatment in the emergency department.

  2024cites this paper
• Causality between migraine and cardiovascular disease: a bidirectional Mendelian randomization study

  2024cites this paper
• Pharmacology of erenumab in human isolated coronary and meningeal arteries: Additional effect of gepants on top of a maximum effect of erenumab

  2024cites this paper
• Real-world study of adverse events associated with triptan use in migraine treatment based on the U.S. Food and Drug Administration (FDA) adverse event reporting system (FAERS) database

  2024cites this paper
• Neurophysiological and Vascular Mechanisms of Action of Serotoninergic Drugs for Abortive Migraine Treatment

  2024cites this paper
• Cardiovascular adverse events associated with triptans for treatment of migraine: a pharmacovigilance study of the FDA adverse event reporting system (FAERS).

  2024cites this paper
• A Review Article on Migrane

  2023cites this paper
• Nanostructured cubosomal in situ nasal gel for the treatment of migraine

  2023cites this paper
• Migraine and cardiovascular disease: what cardiologists should know.

  2023cites this paper
• Update of Gepants in the Treatment of Chronic Migraine

  2023cites this paper
• Towards precision medicine in migraine: Recent therapeutic advances and potential biomarkers to understand heterogeneity and treatment response.

  2023cites this paper
• Microembolism and Other Links Between Migraine and Stroke

  2022cites this paper
• Calcitonin gene-related peptide and neurologic injury: An emerging target for headache management.

  2022cites this paper
• A rare complication of coronary vasospasm associated with concomitant use of ergotamine, cobicistat, and darunavir

  2022cites this paper
• An outlook on the trigeminovascular mechanisms of action and side effects concerns of some potential neuropeptidergic antimigraine therapies

  2021cites this paper
• Current advances in the management of cluster headaches

  2021cites this paper
• Drug interactions and risks associated with the use of triptans, ditans and monoclonal antibodies in migraine

  2021cites this paper
• Relationship between coronary function testing and migraine: results from the Women’s Ischemia Syndrome Evaluation-Coronary Vascular Dysfunction project

  2021cites this paper
• Naratriptan is as effective as sumatriptan for the treatment of migraine attacks when used properly. A mini-review

  2021cites this paper
• Quick Reference Guides of Commonly Prescribed Drugs and Doses

  2021cites this paper
• Migraine

  2021cites this paper
• Disease of the Year 2019 Revisited : Migraine Section Editors :

  2020cites this paper
• Therapeutic Management: When and What

  2020cites this paper
• Recent Advances in the Management of Migraine in Older Patients

  2020cites this paper
• Peripheral projections of the trigeminovascular system as antimigraine target

  2020cites this paper
• Pharmacological strategies to treat attacks of episodic migraine in adults

  2020cites this paper
• Lasmiditan: Its Development and Potential Use

  2020cites this paper
• Emerging Treatment Options for Migraine.

  2020cites this paper
• Subcutaneous sumatriptan: association with decreases in postoperative pain and opioid use after elective cranial surgery.

  2020cites this paper
• Lasmiditan in patients with common migraine comorbidities: a post hoc efficacy and safety analysis of two phase 3 randomized clinical trials

  2020cites this paper
• Targeting the 5-HT1B/1D and 5-HT1F receptors for acute migraine treatment.

  2020cites this paper
• Lasmiditan inhibits calcitonin gene-related peptide release in the rodent trigeminovascular system

  2020cites this paper
• Pharmacological treatment of migraine: CGRP and 5-HT beyond the triptans.

  2020cites this paper
• Acute Care Treatment of Migraine.

  2020cites this paper
• Characterisation of the calcitonin gene-related peptide receptor antagonists ubrogepant and atogepant in human isolated coronary, cerebral and middle meningeal arteries

  2020cites this paper
• Nonclinical safety evaluation of erenumab, a CGRP receptor inhibitor for the prevention of migraine.

  2019cites this paper
• The need for new acutely acting antimigraine drugs: moving safely outside acute medication overuse

  2019cites this paper
• Targeting CGRP and 5‐HT1F Receptors for the Acute Therapy of Migraine: A Literature Review

  2019cites this paper
• Characterization of binding, functional activity, and contractile responses of the selective 5‐HT1F receptor agonist lasmiditan

  2019cites this paper
• Headache, Facial Pain, and Disorders of Facial Sensation

  2019cites this paper
• Effects of two isometheptene enantiomers in isolated human blood vessels and rat middle meningeal artery – potential antimigraine efficacy

  2019cites this paper
• Pharmacokinetics and pharmacodynamics of new acute treatments for migraine

  2019cites this paper
• Therapeutic novelties in migraine: new drugs, new hope?

  2019cites this paper
• Why is the therapeutic effect of acute antimigraine drugs delayed? A review of controlled trials and hypotheses about the delay of effect

  2019cites this paper
• Kampo extract goshuyuto for prevention of paroxysmal atrial fibrillation associated with migraine attack

  2018cites this paper
• Side effects associated with current and prospective antimigraine pharmacotherapies

  2018influential citation
• Serotonin receptor agonists in the acute treatment of migraine: a review on their therapeutic potential

  2018cites this paper
• Targeted 5-HT1F Therapies for Migraine

  2018cites this paper
• Is selective 5‐HT1F receptor agonism an entity apart from that of the triptans in antimigraine therapy?

  2018cites this paper
• Lasmiditan for the treatment of acute migraine: a review and potential role in clinical practice

  2018cites this paper
• A human trigeminovascular biomarker for antimigraine drugs: A randomised, double-blind, placebo-controlled, crossover trial with sumatriptan

  2017cites this paper
• Pharmacological Management of Migraine

  2017cites this paper
• Increased rate of venous thrombosis may be associated with inpatient dihydroergotamine treatment

  2017cites this paper
• Lasmiditan for the treatment of migraine

  2017cites this paper
• The role of α1- and α2-adrenoceptor subtypes in the vasopressor responses induced by dihydroergotamine in ritanserin-pretreated pithed rats

  2017cites this paper
• Migraine Treatment: Current Acute Medications and Their Potential Mechanisms of Action

  2017cites this paper
• Trigeminovascular calcitonin gene-related peptide function in Cacna1a R192Q-mutated knock-in mice

  2017cites this paper
• Ergot Use and Overuse: A Pharmacoepidemiology Retrospective Cohort Study

  2016cites this paper
• Intranasal Pharmacokinetic Data for Triptans Such as Sumatriptan and Zolmitriptan Can Render Area Under the Curve (AUC) Predictions for the Oral Route: Strategy Development and Application

  2016cites this paper
• Migraine in the era of precision medicine.

  2016cites this paper
• Ergot Alkaloids: A Review on Therapeutic Applications

  2016cites this paper
• Background of the Problem Selected for the Research

  2015cites this paper
• The effect of zolmitriptan on cardiac autonomic modulation in patients with migraine: A double-blind, placebo-controlled, crossover study.

  2015cites this paper
• Microvasculature, the Trigeminal System and Migraine : A focus on female sex hormones

  2015cites this paper
• ST-Elevation Myocardial Infarction After Sumitriptan Ingestion in Patient with Normal Coronary Arteries

  2015cites this paper
• Dihydroergotamine and sumatriptan in isolated human coronary artery, middle meningeal artery and saphenous vein

  2015influential citation
• Review of dose–response curves for acute antimigraine drugs: triptans, 5-HT1F agonists and CGRP antagonists

  2015cites this paper
• Interaction of Isoflavones and Endophyte-Infected Tall Fescue Seed Extract on Vasoactivity of Bovine Mesenteric Vasculature

  2015cites this paper
• New Therapeutic Approaches for the Treatment of Migraine

  2015cites this paper
• Takotsubo Syndrome (or Apical Ballooning Syndrome) Secondary to Zolmitriptan

  2015cites this paper
• Headache, Cerebral Aneurysms, and the Use of Triptans and Ergot Derivatives

  2015cites this paper
• Canadian Headache Society systematic review and recommendations on the treatment of migraine pain in emergency settings

  2015cites this paper
• What can data mining teach us about triptan safety that we don’t already know?

  2014cites this paper
• Myokardiale Ischämie als Folge eines übermäßigen Gebrauchs von Kopfschmerzmedikamenten

  2014cites this paper
• Novel strategies for the treatment of migraine attacks via the CGRP, serotonin, dopamine, PAC1, and NMDA receptors

  2014cites this paper
• Drugs targeting 5-hydroxytryptamine receptors in acute treatments of migraine attacks. A review of new drugs and new administration forms of established drugs

  2014cites this paper
• [Myocardial ischemia caused by overuse of headache medications].

  2014cites this paper
• Cranioselectivity of Sumatriptan Revisited: Pronounced Contractions to Sumatriptan in Small Human Isolated Coronary Artery

  2014cites this paper
• Sumatriptan and dihydroergotamine in proximal and distal human isolated coronary arteries

  2013cites this paper
• Familial and Sporadic Hemiplegic Migraine: Diagnosis and Treatment

  2013cites this paper
• Chest pain with normal coronary arteries

  2013cites this paper
• QT Prolongation, Torsade de Pointes, Myocardial Ischemia From Coronary Vasospasm, and Headache Medications. Part 1: Review of Serotonergic Cardiac Adverse Events With a Triptan Case

  2013cites this paper
• Non-Cardiac Chest Pain of Non-Esophageal Origin

  2013cites this paper
• Increased tissue angiotensin-converting enzyme activity impairs bradykinin-induced dilation of coronary arterioles in obesity.

  2013cites this paper
• Distribution of CGRP and CGRP receptor in the trigeminovascular system and CNS

  2013cites this paper
• Kinetics of 5-HT2B Receptor Signaling: Profound Agonist-Dependent Effects on Signaling Onset and Duration

  2013cites this paper
• Pharmacological Acute Migraine Treatment Strategies: Choosing the Right Drug for a Specific Patient

  2013cites this paper
• Relatively slow and long-lasting antimigraine effect of dihydroergotamine is most likely due to basic pharmacological attributes of the drug: A review

  2013cites this paper
• Discovery techniques for calcitonin gene-related peptide receptor antagonists for potential antimigraine therapies

  2013cites this paper
• Canadian Headache Society Guideline: Acute Drug Therapy for Migraine Headache

  2013cites this paper
• Triptans and ergot alkaloids in the acute treatment of migraine: similarities and differences

  2013cites this paper
• Activation of 5-hydroxytryptamine1B/1D/1F receptors as a mechanism of action of antimigraine drugs

  2013cites this paper
• Sumatriptan: a review of its pharmacokinetics, pharmacodynamics and efficacy in the acute treatment of migraine

  2013cites this paper
• Almotriptan

  2012cites this paper
• Rizatriptan

  2012cites this paper